LAVIPHARM S.A. NA EO 1 (BXA0) - Total Liabilities
Based on the latest financial reports, LAVIPHARM S.A. NA EO 1 (BXA0) has total liabilities worth €72.52 Million EUR (≈ $84.78 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BXA0 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
LAVIPHARM S.A. NA EO 1 - Total Liabilities Trend (2021–2024)
This chart illustrates how LAVIPHARM S.A. NA EO 1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LAVIPHARM S.A. NA EO 1 balance sheet assets.
LAVIPHARM S.A. NA EO 1 Competitors by Total Liabilities
The table below lists competitors of LAVIPHARM S.A. NA EO 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cahya Mata Sarawak Bhd
KLSE:2852
|
Malaysia | RM801.52 Million |
|
Oyster Enterprises II Acquisition Corp Class A Ordinary Shares
NASDAQ:OYSE
|
USA | $8.97 Million |
|
Kochav Defense Acquisition Corp. Class A Ordinary Shares
NASDAQ:KCHV
|
USA | $6.99 Million |
|
Chia Hsin Cement Corp
TW:1103
|
Taiwan | NT$14.45 Billion |
|
Changzhou Tiansheng New Materials Co Ltd
SHE:300169
|
China | CN¥579.11 Million |
|
Shanghai Mechanical & Electrical Industry Co Ltd B
SHG:900925
|
China | $15.81 Billion |
|
Studio City International Holdings Ltd
NYSE:MSC
|
USA | $2.16 Billion |
|
Mesabi Trust
NYSE:MSB
|
USA | $3.58 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down LAVIPHARM S.A. NA EO 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LAVIPHARM S.A. NA EO 1 balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LAVIPHARM S.A. NA EO 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below shows the annual total liabilities of LAVIPHARM S.A. NA EO 1 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €72.52 Million ≈ $84.78 Million |
+0.70% |
| 2023-12-31 | €72.02 Million ≈ $84.19 Million |
-2.49% |
| 2022-12-31 | €73.86 Million ≈ $86.34 Million |
+17.83% |
| 2021-12-31 | €62.68 Million ≈ $73.28 Million |
-- |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more